Human CXCR4 / CD184 Full Length Protein (VLP), Unconjugated

Artikelnummer: ABS-CX4-H5219-500UG
Artikelname: Human CXCR4 / CD184 Full Length Protein (VLP), Unconjugated
Artikelnummer: ABS-CX4-H5219-500UG
Hersteller Artikelnummer: CX4-H5219-500ug
Alternativnummer: ABS-CX4-H5219-500UG
Hersteller: AcroBiosystems
Wirt: Human
Kategorie: Proteine/Peptide
Spezies Reaktivität: Human
Konjugation: Unconjugated
CXC chemokine receptor type 4 is also known as fusin or CD184 (cluster of differentiation 184), CXCR4, CD184, D2S201E, FB22, HM89, HSY3RR, LAP3, LCR1, LESTR, NPY3R, NPYR, NPYRL, NPYY3R or WHIM. CXCR4 is an alphachemokine receptor specific for stromalderivedfactor1 (SDF1 also called CXCL12), a molecule endowed with potent chemotactic activity for lymphocytes. This receptor is one of several chemokine receptors that HIV isolates can use to infect CD4+ T cells. HIV isolates that use CXCR4 are traditionally known as Tcell tropic isolates. Typically, these viruses are found late in infection. It is unclear as to whether the emergence of CXCR4 using HIV is a consequence or a cause of immunodeficiency.CXCR4 is upregulated during the implantation window in natural and hormone replacement therapy cycles in the endometrium, producing, in presence of a human blastocyst, a surface polarization of the CXCR4 receptors suggesting that this receptor is implicated in the adhesion phase of human implantation. SDF1 and CXCR4 were believed to be a relatively monogamous ligandreceptor pair (other chemokines tend to use several different chemokine receptors in a fairly promiscuous manner). Recent evidence demonstrates ubiquitin is also a natural ligand of CXCR4. Chronic exposure to THC increased T lymphocyte CXCR4 expression on both CD4+ and CD8+ T lymphocytes. Drugs that block the CXCR4 receptor appear to be capable of mobilizing hematopoietic stem cells into the bloodstream as peripheral blood stem cells. - Proteine/Peptide
NCBI: 61073
Puffer: PBS, pH7.4
Formulierung: Liquid
Target-Kategorie: CXCR4
Immobilized Human CXCR4 Full Length Protein-VLP (Cat. No. CX4-H5219) at 5 µg/mL (100 µL/well) can bind Human ulocuplumab, Human IgG4 with a linear range of 1-31 ng/mL (QC tested).